Search results for "Brachial Plexus Neuritis"

showing 7 items of 7 documents

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

2019

Background: Successful tyrosine-kinase inhibitors (TKIs) discontinuation has been obtained in some patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML). Careful molecular monitoring after discontinuation is the key to guarantee the safety, in terms of prompt resumption of therapy according to retreatment threshold criteria. It was observed that the majority of relapses usually occur during the first 6 months after TKI discontinuation [Saussele S, Lancet Oncol 2018; Etienne G, JCO 2017], accounting for the monthly quantitative PCR (qPCR) that all prospective protocols included in the trial design at least during the first half-year. Two studies [Kong HJ, Cancer 2017; Shanmugan…

Brachial Plexus NeuritisPediatricsmedicine.medical_specialtyMeasles-Mumps-Rubella Vaccinebusiness.industryImmunologyMyeloid leukemiaCancerCell BiologyHematologymedicine.diseaseBiochemistrylaw.inventionDiscontinuationlawRetrospective analysisMedicinebusinessPolymerase chain reactionBlood
researchProduct

Gender-specific diagnosis of acute myocardial infarction using high-sensitivity assayed cardiac troponin I

2013

Brachial Plexus Neuritismedicine.medical_specialtyCardiac troponinPositive pressure ventilatorsbusiness.industryInternal medicineCardiologyMedicineMyocardial infarctionCardiology and Cardiovascular Medicinebusinessmedicine.diseaseEuropean Heart Journal
researchProduct

P1475Impact of automatic screening and parasternal rights positions in the eligibility of patients with hypertrophic cardiomyopathy for subcutaneous …

2020

Abstract Background A high percentage of failures in the detection of QRS and T wave in patients (pts) with hypertrophic cardiomyopathy (HCM) have been reported. This finding would prevent them from being eligible for an implantable subcutaneous automatic defibrillator (S-ICD). However, recently 2 changes in the detection have been proposed, automatic screening and the use of right parasternal position of the lead.  The aim of our work was to study if the elegibility proportion of patients  was increased with both 2 advacements. Methods We included 31 patients (18 male)with a diagnosis of HCM and at least 1 risk factor for sudden death, in follow-up at the outdoor clinic of of 2 cardiology …

Brachial Plexus Neuritismedicine.medical_specialtySupine positionScreening testbusiness.industryHypertrophic cardiomyopathymedicine.diseaseSudden deathParasternal linePhysiology (medical)Internal medicinemedicineCardiologyImplantCardiology and Cardiovascular MedicinebusinessEP Europace
researchProduct

Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal …

2018

Brachial Plexus Neuritismedicine.medical_specialtybusiness.industryPhases of clinical researchHematologyGastroenterology03 medical and health sciencesLarge Intestine Adenocarcinomachemistry.chemical_compound0302 clinical medicineOncologychemistry030220 oncology & carcinogenesisInternal medicineRegorafenibmedicine030211 gastroenterology & hepatologyColorectal adenocarcinomaIn patientPreviously treatedbusinessAnnals of Oncology
researchProduct

Clinico-diagnostic features of neuralgic amyotrophy in childhood

2020

Neuralgic amyotrophy (NA), even known as Personage-Turner's syndrome (PTS), is a neurologic condition, affecting the lower motor neurons of brachial plexus and/or individual nerves or nerve branches, characterized by pain, muscle weakness/atrophy, and sensory symptoms. NA has an acute/subacute onset, after an infection or vaccination; it is more common in male and is rare in the pediatric population. The etiology remains uncertain, being considered heterogeneous and multifactorial. A severe acute neurologic pain around the shoulder girdle is the classic presenting symptom at onset. As the pain subsides, weakness and paresis develop. NA is usually unilateral, but sometimes, a subclinical con…

MalePediatricsmedicine.medical_specialtyWeaknessNeurologyPainNeurological examinationDermatology03 medical and health sciences0302 clinical medicineElectromyography; Neuralgic amyotrophy; Neuralgic pain; Pediatric; Personage-Turner’s syndromemedicineHumansBrachial Plexus NeuritisBrachial Plexus030212 general & internal medicineChildParesisPediatricMuscle Weaknessmedicine.diagnostic_testbusiness.industryElectromyographyPersonage-Turner’s syndromeMuscle weaknessGeneral MedicineNeuralgic amyotrophyDiagnosis of exclusionPsychiatry and Mental healthMuscular AtrophySettore MED/26 - NeurologiaNeurology (clinical)Differential diagnosismedicine.symptombusinessBrachial plexusNeuralgic pain030217 neurology & neurosurgery
researchProduct

P-066 S-1 in combination with epirubicin and oxaliplatin (EOS) in Caucasian patients (pts) with advanced or metastatic gastric cancer (AGC): Results …

2015

OncologyBrachial Plexus Neuritismedicine.medical_specialtybusiness.industryHematologyOxaliplatinMetastatic gastric cancerPhase i studyOncologyInternal medicinemedicinebusinessmedicine.drugEpirubicinAnnals of Oncology
researchProduct

Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung…

2015

8073 Background: Afatinib 40 mg/day (oral) is approved for the treatment of pts with advanced EGFRm+ NSCLC. Dose adjustment is recommended according to pre-defined tolerability criteria. We perform...

Pulmonary and Respiratory MedicineBrachial Plexus NeuritisOncologyCancer Researchmedicine.medical_specialtybusiness.industryAfatinibMedizinnon-small cell lung cancer (NSCLC)HematologyPharmacologymedicine.diseasestomatognathic diseasesTolerabilityOncologyEgfr mutationDose adjustmentInternal medicinemedicineIn patientbusinessmedicine.drug
researchProduct